Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Astec Lifesciences Limited ( (IN:ASTEC) ).
Astec LifeSciences Limited’s board has approved the audited standalone and consolidated financial results for the quarter and full year ended 31 March 2026, along with the cash flow statement and statement of assets and liabilities. The statutory auditors issued unmodified opinions on these results, underscoring the integrity of the company’s financial reporting and providing reassurance to investors and lenders.
The board has scheduled the 32nd Annual General Meeting for 31 July 2026, with book closure set from 26 to 30 July 2026 for shareholder entitlement purposes. Directors also cleared a postal ballot to seek shareholder approval for multiple governance items, including several board appointments and remuneration changes, as well as authorization for material related-party transactions in FY 2026-27, signalling ongoing board refreshment and a formalized approach to intra-group dealings.
More about Astec Lifesciences Limited
Astec LifeSciences Limited operates in the agrochemicals and lifesciences sector, producing active ingredients and intermediates used in crop protection and related applications. The company focuses on supplying technical grade products and formulations to domestic and international markets, aligning with the wider Godrej Group’s presence in chemicals and agriculture inputs.
Average Trading Volume: 13,048
Technical Sentiment Signal: Sell
Current Market Cap: 16.1B INR
See more insights into ASTEC stock on TipRanks’ Stock Analysis page.